Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Trial of Immune Modulation in Combination With Ultrasound-mediated Blood Brain Barrier Opening in Patients With Newly Diagnosed Glioblastoma

NCT05864534 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT05864534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05864534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Trial of Immune Modulation in Combination With Ultrasound-mediated Blood Brain Barrier Opening in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 19, 2024
Completion date
August 31, 2031
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, glioblastoma, isocitric dehydrogenase (idh)-wildtype, gliosarcoma, newly diagnosed glioblastoma